Ex vivo binding of the immunosuppressant mycophenolic acid to dog and cat plasma proteins and the effect of co‐incubated dexamethasone and prednisolone. Issue 4 (23rd April 2018)

• Record Type: Journal Article
• Authors: Morassi, A.; Rivera-Vélez, S. M.; Slovak, J. E.; Court, M. H.; Villarino, N. F.
• Is Part Of: Journal of veterinary pharmacology and therapeutics. Volume 41:Issue 4(2018)
• Page Start: 513
• Page End: 521
• Publication Date: 2018-04-23
• Subjects: cats -- corticosteroids -- dogs -- mycophenolic acid -- protein binding; Veterinary pharmacology -- Periodicals; Therapeutics -- Periodicals; 636.0895105
• DOI: 10.1111/jvp.12507
• Languages: English
• ISSNs: 0140-7783

Abstract

Abstract : Mycophenolic acid (MPA) has been shown to be promising for the treatment of autoimmune diseases in dogs and cats. In humans, MPA is highly bound to plasma proteins (~97%). It has been recommended to monitor free drug plasma concentrations because the free MPA correlates with its immunosuppressive effect. However, it is unknown if MPA is highly bound to plasma proteins in dogs and cats. The objectives of this study were to determine the extent of plasma protein binding of MPA and evaluate the effect of prednisolone and dexamethasone on the extent of protein binding of MPA in dogs and cats. The extent of plasma protein binding of MPA was determined in plasma collected from clinically healthy adult cats ( n = 13) and dogs ( n = 14) by combining high‐throughput dialysis and ultra‐high‐liquid chromatography. This study reveals that MPA is highly bound to plasma proteins (>90%) in dogs and cats, mean extent of binding of MPA at 15 μg/ml to plasma proteins being 96% (range, 95%–97%) and 92% (range, 90%–93%) for dogs and cats, respectively. In dog plasma, MPA is primarily bound to albumin. In vitro, prednisolone increased the unbound MPA in dogs ( p < .01) but not in cats ( p = .07) while dexamethasone had no effect on MPA plasma binding in either species ( p > .05). Results of this study provide valuable information for designing future pharmacokinetic and pharmacodynamic studies and also therapeutic monitoring programs for dogs and cats.